Large-scale worldwide observational study of adherence with acne therapy

Authors

  • Brigitte Dréno MD, PhD,

    1. Department of Dermatolgy, Nantes University Hospital, Hôtel-Dieu, Nantes, France
    Search for more papers by this author
  • Diane Thiboutot MD,

    1. Department of Dermatology, Penn State University College of Medicine, Hershey, PA, USA
    Search for more papers by this author
  • Harald Gollnick MD,

    1. Department of Dermatology and Venereology, Otto von Guericke University, Magdeburg, Germany
    Search for more papers by this author
  • Andrew Y. Finlay MB BS, FRCP,

    1. Department of Dermatology, Cardiff University School of Medicine, Cardiff, UK
    Search for more papers by this author
  • Alison Layton MB, ChB, FRCP,

    1. Harrogate and District Foundation Trust, Harrogate, UK
    Search for more papers by this author
  • James J. Leyden MD,

    1. Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA
    Search for more papers by this author
  • Eric Leutenegger PhD,

    1. ABR Pharma, Paris, France
    Search for more papers by this author
  • Montserrat Perez MD,

    1. Clinical Dermatologica de Moragas, Barcelona, Spain
    Search for more papers by this author
  • on behalf of the Global Alliance to Improve Outcomes in Acne

    Search for more papers by this author
    • *

      The Global Alliance to Improve Outcomes in Acne is an international committee of physicians and researchers in the field of acne. Global Alliance to Improve Outcomes in Acne members: Harald Gollnick, MD, Chair; Diane Thiboutot, MD, Co-Chair; Vincenzo Bettoli, MD; Brigitte Dréno, MD, PhD; Sewon Kang, MD; James J. Leyden, MD; Alan R. Shalita, MD; Vicente Torres Lozada, MD, Steering Committee; Diane Berson, MD; Alejandro Cordero, MD; Andrew Finlay, MB BS, FRCP; Chee Leok Goh, MD, MRCP, FRCP, FAMS; Maria Isabel Herane, MD; Ana Kaminsky, MD, PhD; Raj Kubba, MD; Alison Layton, MB, ChB, FRCP; Yoshiki Miyachi, MD, PhD; Montserrat Perez, MD; Jaime Piquero-Martin, MD; Marcia Ramos-e- Silva, MD, PhD; Jo Ann See, MBBS, FACD; Neil Shear, MD; John Wolf, Jr, MD.


Professor Brigitte Dréno, MD, PhD
Unité de Cancérologie cutanée, Hôtel-Dieu
Place Alexis Ricordeau,
44093 Nantes Cedex 01, France
E-mail: brigitte.dreno@wanadoo.fr

Abstract

Acne is a common chronic disease that typically requires prolonged treatment. Several small studies conducted over the past few years suggest that adherence to acne medications is often poor. In addition, data regarding the factors that positively or negatively impact adherence in patients with acne are sparse. This study utilized a simple, validated questionnaire (ECOB, Elaboration d’un outil d’evaluation de l’observance des traitements medicamenteux) to assess the risk of poor adherence in a large worldwide cohort of acne patients (n = 3339) from three major geographic regions [the Americas (n = 952), Europe (n = 1196), and Asia (n = 1191). In addition, information about patient and treatment characteristics was collected to identify factors that correlated with adherence. Overall, there was a poor adherence rate of 50% in this study; this varied by region, with significantly worse adherence in Europe versus Asia and America (poor adherence rates of 58%, 48%, and 43%, respectively, P < 0.0001). To provide insight into factors that affect medication-taking behavior in acne, adherence was analyzed by the type of treatment (a combination of topical and systemic, topical only, oral isotretinoin). Among patients taking a combination of both systemic and topical therapy, 60% (n = 944) of patients had poor adherence to at least one treatment as defined in the study protocol. In this group, there was a higher proportion of patients who had poor adherence to systemic treatment versus topical treatment (54% vs. 44%, respectively). Among patients treated with topical therapy only, poor adherence occurred in 40% (n = 356) of cases. A total of 46% (n = 325) of patients using oral isotretinoin therapy had poor adherence. Multivariate analysis showed that poor adherence was independently correlated with young age (most strongly with <15 years but also in the age group from 15 to 25 years), the occurrence of side effects, lack of improvement as evaluated by dermatologist, previous systemic therapy, lack of knowledge about acne treatment, consultation with a primary care physician, and lack of patient satisfaction with treatment. Factors that had a positive effect on adherence were more severe acne, use of cosmetics (moisturizers, cleansers), use of either topical therapy alone or isotretinoin, good clinical improvement as evaluated by the dermatologist, patient satisfaction with therapy, and knowledge of acne treatment.

Ancillary